PMS37 Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in Kazakhstan
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Value in Health
Abstract
The purpose of present study was to evaluate the cost-effectiveness of tocilizumab (TCZ) vs. infliximab (IFX) for the treatment of patients with rheumatoid arthritis (RA) from the perspective of Ministry of Health (MoH) over a patient lifetime horizon in Kazakhstan.
Description
Keywords
Citation
C. Bektur, F. Kayir, T. Nurgozhin, PMS37 - Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in Kazakhstan, In Value in Health, Volume 17, Issue 7, 2014, Page A379